Journal List > Lab Med Online > v.6(4) > 1057326

Ahn, Chang, Sung, and Kim: A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim/Sulfamethoxazole in the Absence of Previous Drug Exposure

Abstract

Pneumocystis jirovecii pneumonia is a common opportunistic infection seen in patients with human immunodeficiency virus (HIV) infection. Dihydropteroate synthase (DHPS) is a target of sulfa drugs, and mutations in DHPS gene are associated with failure in treatment and prophylaxis of P. jirovecii infections in HIV-infected patients. Here, we report a case of a patient with P. jirovecii infection, harboring DHPS gene mutations, who had not been previously treated with trimethoprim/sulfamethoxazole (TMP/SMX). A 50-yr-old man was admitted to the hospital with symptoms such as fever, cough, sputum, and sore throat. Chest computed tomography scanning revealed diffuse ground glass opacity in both the lungs, and the patient was diagnosed as having HIV infection with a CD4+ T cell count of 22/µL. Immunohistochemical test results were positive for P. jirovecii. He was treated with TMP/SMX; however, his symptoms and laboratory findings did not improve. The treatment was changed to clindamycin and primaquine, and his symptoms improved after 3 days. Molecular testing of the sample for the detection of DHPS gene mutations and the typing of mitochondrial large subunit rRNA (mtlsurRNA) revealed DHPS gene mutations at codon 55 and 57, respectively, and the case had type 3 mtlsurRNA. This case study illustrates that DHPS mutation test results can be positive even in patients without previous exposure to TMP/SMX.

Figures and Tables

Fig. 1

Initial chest computed tomography reveals diffuse ill-defined ground glass opacities in both lungs, which indicates atypical pneumonia caused by cytomegalovirus or Pneumocystis.

lmo-6-250-g001
Fig. 2

Immunohistochemical stain of organism clusters from bronchoalveolar lavage using Pneumocystis jirovecii Clone 3F6 (DAKO Corp., Carpinteria, Calif., USA) (×400).

lmo-6-250-g002
Fig. 3

DHPS mutation study of the patient shows synonymous mutation of Thr55Ala and Pro57Ser. The electropherogram indicates there are alanine and serine in 55th and 57th codon, respectively, instead of threonine and proline in wild type.

lmo-6-250-g003

Notes

This article is available from http://www.labmedonline.org

References

1. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988; 334:519–522.
crossref
2. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002; 8:891–896.
3. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009; 58:1–207. quiz CE1-4.
crossref
4. Lane BR, Ast JC, Hossler PA, Mindell DP, Bartlett MS, Smith JW, et al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis. 1997; 175:482–485.
5. Volpe F, Dyer M, Scaife JG, Darby G, Stammers DK, Delves CJ. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii appears to encode dihydropteroate synthase and hydroxymethyldihydropterin pyrophosphokinase. Gene. 1992; 112:213–218.
crossref
6. Walker DJ, Meshnick SR. Drug resistance in Pneumocystis carinii: an emerging problem. Drug Resist Updat. 1998; 1:201–204.
7. Bellamy RJ. HIV: treating Pneumocystis pneumonia (PCP). BMJ Clin Evid. 2008; 2008.
8. Lee SM, Cho YK, Sung YM, Chung DH, Jeong SH, Park JW, et al. A case of pneumonia caused by Pneumocystis jirovecii resistant to trimethoprim-sulfamethoxazole. Korean J Parasitol. 2015; 53:321–327.
crossref
9. Melanie TU. Pneumocystis. In : Versalovic J, editor. Manual of clinical microbiology. 10th ed. Washington, D.C.: ASM Press;2011.
10. Gajdusek DC. Pneumocystis carinii; etiologic agent of interstitial plasma cell pneumonia of premature and young infants. Pediatrics. 1957; 19:543–565.
crossref
11. Wilkin A, Feinberg J. Pneumocystis carinii pneumonia: a clinical review. Am Fam Physician. 1999; 60:1699–1708. 1713–1714.
12. Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis. 2003; 36:70–78.
crossref
13. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998; 12:873–878.
crossref
14. Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996; 124:792–802.
crossref
15. Hauser PM, Nahimana A, Taffe P, Weber R, Francioli P, Bille J, et al. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. Clin Infect Dis. 2010; 51:e28–e33.
16. Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis. 2000; 6:265–272.
crossref
17. Kim T, Lee SO, Hong HL, Lee JY, Kim SH, Choi SH, et al. Clinical characteristics of hospital-onset Pneumocystis pneumonia and genotypes of Pneumocystis jirovecii in a single tertiary centre in Korea. BMC Infect Dis. 2015; 15:102.
crossref
TOOLS
Similar articles